HPV16-POSITIVE OROPHARYNGEAL SQUAMOUS-CELL CARCINOMA
Clinical trials for HPV16-POSITIVE OROPHARYNGEAL SQUAMOUS-CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new HPV16-POSITIVE OROPHARYNGEAL SQUAMOUS-CELL CARCINOMA trials appear
Sign up with your email to follow new studies for HPV16-POSITIVE OROPHARYNGEAL SQUAMOUS-CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to supercharge immune system against HPV throat cancer
Disease control Recruiting nowThis study tests an experimental drug called CUE-101 in 30 people with HPV16-positive throat cancer. The drug is given before standard treatments like surgery or chemoradiation to see if it safely boosts the body's immune cells to fight the cancer. Researchers will monitor side e…
Matched conditions: HPV16-POSITIVE OROPHARYNGEAL SQUAMOUS-CELL CARCINOMA
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Immunotherapy plus chemo shows promise in shrinking HPV throat tumors before surgery
Disease control Recruiting nowThis Phase 2 trial is testing whether giving the immunotherapy drug toripalimab along with standard chemotherapy before surgery or radiation can shrink HPV16-positive oropharyngeal (throat) tumors by at least 50%. The study enrolls 30 patients with advanced but localized disease.…
Matched conditions: HPV16-POSITIVE OROPHARYNGEAL SQUAMOUS-CELL CARCINOMA
Phase: PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New vaccine aims to train immune system against HPV throat cancer
Disease control Recruiting nowThis study tests a vaccine designed to help the immune system fight HPV-positive throat cancer. It is for patients who have completed surgery or chemoradiation and show no signs of cancer remaining. The trial will enroll 24 adults to find the safest and most effective dose by mea…
Matched conditions: HPV16-POSITIVE OROPHARYNGEAL SQUAMOUS-CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC